Stratipath utilizes deep learning algorithms to perform risk profiling of cancer tumors, providing healthcare and life science companies with precise diagnostic insights. This technology enables faster and more affordable tumor analysis compared to traditional methods, improving patient access to critical diagnostic information.
Funding
$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for assessing cancer tumor risk, such as gene expression testing, can be expensive, time-consuming, and inaccessible to many patients. This can lead to delays in treatment decisions and potential over- or under-treatment based on incomplete information. A significant portion of breast cancer patients are categorized as intermediate risk, providing limited clinical utility for treatment planning.
Solution
Stratipath offers an AI-based precision diagnostic software platform that analyzes routine histology images to provide risk profiling of cancer tumors. The platform leverages deep learning algorithms to identify morphological patterns associated with risk, enabling faster and more affordable tumor analysis compared to traditional methods. Stratipath Breast, the company's flagship product, is a CE-IVD marked solution that analyzes digitized HE-stained slides from breast cancer biopsies to classify tumors into low- or high-risk categories. This AI-driven approach provides clinicians with objective, prognostic information to support treatment decisions and improve patient outcomes, while reducing the need for costly and time-consuming gene expression assays.
Target Audience
The primary target audience includes healthcare providers such as oncologists and pathologists, as well as clinical laboratories and pharmaceutical companies involved in cancer diagnostics and treatment.
Features
- AI-powered analysis of routine HE-stained histopathology images
- Prognostic risk profiling of invasive breast cancer, classifying tumors into low- or high-risk categories
- CE-IVD marked for clinical use in the EU and the UK
- Integration with leading digital pathology solutions (Proscia, Sectra, Roche, Paige)
- Web-based portal for standalone use, accessible regardless of image management system
- Rapid analysis, providing results within the hour
- PDF report output, easily shareable and includable in diagnostic reports
- Quality control features for pathologists to verify analyzed image areas
- Biopsy capability for AI diagnostic solution